NO323532B1 - Fremgangsmate for identifisering av kjemoterapeutiske midler ved bruk av transkripsjonsfaktor DP-1 - Google Patents
Fremgangsmate for identifisering av kjemoterapeutiske midler ved bruk av transkripsjonsfaktor DP-1 Download PDFInfo
- Publication number
- NO323532B1 NO323532B1 NO19951641A NO951641A NO323532B1 NO 323532 B1 NO323532 B1 NO 323532B1 NO 19951641 A NO19951641 A NO 19951641A NO 951641 A NO951641 A NO 951641A NO 323532 B1 NO323532 B1 NO 323532B1
- Authority
- NO
- Norway
- Prior art keywords
- protein
- dna
- binding
- complex
- drtf1
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 29
- 239000002246 antineoplastic agent Substances 0.000 title claims description 9
- 229940127089 cytotoxic agent Drugs 0.000 title claims description 9
- 102000004853 Transcription Factor DP1 Human genes 0.000 title description 7
- 108090001097 Transcription Factor DP1 Proteins 0.000 title description 7
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 95
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 90
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 79
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 60
- 229920001184 polypeptide Polymers 0.000 claims abstract description 49
- 239000012634 fragment Substances 0.000 claims abstract description 27
- 102100024026 Transcription factor E2F1 Human genes 0.000 claims abstract description 9
- 230000004568 DNA-binding Effects 0.000 claims description 112
- 230000000694 effects Effects 0.000 claims description 82
- 230000027455 binding Effects 0.000 claims description 46
- 238000009739 binding Methods 0.000 claims description 44
- 150000001413 amino acids Chemical class 0.000 claims description 26
- 108020001507 fusion proteins Proteins 0.000 claims description 22
- 102000037865 fusion proteins Human genes 0.000 claims description 22
- 210000005253 yeast cell Anatomy 0.000 claims description 19
- 238000001727 in vivo Methods 0.000 claims description 17
- 230000003612 virological effect Effects 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 6
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 229920002401 polyacrylamide Polymers 0.000 claims description 4
- 230000002062 proliferating effect Effects 0.000 claims description 4
- 108700008625 Reporter Genes Proteins 0.000 claims description 3
- 239000003550 marker Substances 0.000 claims description 3
- 230000002285 radioactive effect Effects 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 9
- 125000003729 nucleotide group Chemical group 0.000 abstract description 16
- 239000002773 nucleotide Substances 0.000 abstract description 15
- 102000040430 polynucleotide Human genes 0.000 abstract description 9
- 108091033319 polynucleotide Proteins 0.000 abstract description 9
- 239000002157 polynucleotide Substances 0.000 abstract description 9
- 230000000295 complement effect Effects 0.000 abstract description 2
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 101710155964 Diuretic hormone 1 Proteins 0.000 description 218
- 101000639778 Drosophila melanogaster RNA polymerase-associated protein Rtf1 Proteins 0.000 description 99
- 101000666370 Homo sapiens Transcription factor Dp-1 Proteins 0.000 description 99
- 102100038130 Transcription factor Dp-1 Human genes 0.000 description 99
- 210000004027 cell Anatomy 0.000 description 77
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 36
- 239000000284 extract Substances 0.000 description 36
- 238000003556 assay Methods 0.000 description 32
- 230000001419 dependent effect Effects 0.000 description 29
- 102100038042 Retinoblastoma-associated protein Human genes 0.000 description 27
- 238000013518 transcription Methods 0.000 description 27
- 230000035897 transcription Effects 0.000 description 27
- 230000002103 transcriptional effect Effects 0.000 description 23
- 239000002299 complementary DNA Substances 0.000 description 20
- 230000002788 anti-peptide Effects 0.000 description 18
- 102100038313 Transcription factor E2-alpha Human genes 0.000 description 16
- 108010057856 Adenovirus E2 Proteins Proteins 0.000 description 15
- 125000000539 amino acid group Chemical group 0.000 description 15
- 230000003993 interaction Effects 0.000 description 15
- 239000012133 immunoprecipitate Substances 0.000 description 13
- 239000013604 expression vector Substances 0.000 description 12
- 102000040945 Transcription factor Human genes 0.000 description 11
- 108091023040 Transcription factor Proteins 0.000 description 11
- 238000001890 transfection Methods 0.000 description 11
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 10
- 210000004962 mammalian cell Anatomy 0.000 description 10
- 108091026890 Coding region Proteins 0.000 description 9
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 9
- 230000022131 cell cycle Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 108010001515 Galectin 4 Proteins 0.000 description 8
- 102100039556 Galectin-4 Human genes 0.000 description 8
- 238000006471 dimerization reaction Methods 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 7
- 241001529936 Murinae Species 0.000 description 7
- 101710176384 Peptide 1 Proteins 0.000 description 7
- 230000006369 cell cycle progression Effects 0.000 description 7
- 238000003119 immunoblot Methods 0.000 description 7
- 238000001114 immunoprecipitation Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 108010091748 peptide A Proteins 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 230000000692 anti-sense effect Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000000833 heterodimer Substances 0.000 description 6
- 108091008819 oncoproteins Proteins 0.000 description 6
- 102000027450 oncoproteins Human genes 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 108010093502 E2F Transcription Factors Proteins 0.000 description 5
- 102000001388 E2F Transcription Factors Human genes 0.000 description 5
- 230000018199 S phase Effects 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 238000004132 cross linking Methods 0.000 description 5
- 229940009976 deoxycholate Drugs 0.000 description 5
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- 201000000582 Retinoblastoma Diseases 0.000 description 4
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 4
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- 241000944683 Bandara Species 0.000 description 3
- 102000016736 Cyclin Human genes 0.000 description 3
- 108050006400 Cyclin Proteins 0.000 description 3
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 3
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 3
- 101000904152 Homo sapiens Transcription factor E2F1 Proteins 0.000 description 3
- 241000701806 Human papillomavirus Species 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 101710128836 Large T antigen Proteins 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000000710 homodimer Substances 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 230000016507 interphase Effects 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000022983 regulation of cell cycle Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000010396 two-hybrid screening Methods 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- FQVLRGLGWNWPSS-BXBUPLCLSA-N (4r,7s,10s,13s,16r)-16-acetamido-13-(1h-imidazol-5-ylmethyl)-10-methyl-6,9,12,15-tetraoxo-7-propan-2-yl-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide Chemical compound N1C(=O)[C@@H](NC(C)=O)CSSC[C@@H](C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@@H]1CC1=CN=CN1 FQVLRGLGWNWPSS-BXBUPLCLSA-N 0.000 description 2
- 102100034035 Alcohol dehydrogenase 1A Human genes 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- 101150012716 CDK1 gene Proteins 0.000 description 2
- 102000005483 Cell Cycle Proteins Human genes 0.000 description 2
- 108010031896 Cell Cycle Proteins Proteins 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- 102000002554 Cyclin A Human genes 0.000 description 2
- 108010068192 Cyclin A Proteins 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 2
- 102100031250 Disks large-associated protein 1 Human genes 0.000 description 2
- 108050003188 Disks large-associated protein 1 Proteins 0.000 description 2
- 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 2
- 101000892220 Geobacillus thermodenitrificans (strain NG80-2) Long-chain-alcohol dehydrogenase 1 Proteins 0.000 description 2
- 101000780443 Homo sapiens Alcohol dehydrogenase 1A Proteins 0.000 description 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 2
- 108010053229 Lysyl endopeptidase Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 108700009124 Transcription Initiation Site Proteins 0.000 description 2
- 101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical group C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 238000001261 affinity purification Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- NVLDXKCJZRQSDJ-UHFFFAOYSA-L cyclohexane-1,2-diamine;2-(1,2-dihydroxyethyl)-3-hydroxy-5-oxo-2h-furan-4-olate;platinum(2+) Chemical compound [Pt+2].NC1CCCCC1N.OCC(O)C1OC(=O)C([O-])=C1O.OCC(O)C1OC(=O)C([O-])=C1O NVLDXKCJZRQSDJ-UHFFFAOYSA-L 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000010399 physical interaction Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000013615 primer Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 210000001995 reticulocyte Anatomy 0.000 description 2
- 102000023888 sequence-specific DNA binding proteins Human genes 0.000 description 2
- 108091008420 sequence-specific DNA binding proteins Proteins 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- JPOKAKNGULMYHZ-UILVTTEASA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]-3-(4-hydroxyp Chemical compound C([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N)C1=CC=C(O)C=C1 JPOKAKNGULMYHZ-UILVTTEASA-N 0.000 description 1
- 108010024878 Adenovirus E1A Proteins Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 108091007914 CDKs Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000004214 DNA polymerase A Human genes 0.000 description 1
- 108090000725 DNA polymerase A Proteins 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 101150009006 HIS3 gene Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101500026142 Homo sapiens Processed cyclic AMP-responsive element-binding protein 3 Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 101800000507 Non-structural protein 6 Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108010057576 Papillomavirus E7 Proteins Proteins 0.000 description 1
- 108010039918 Polylysine Chemical group 0.000 description 1
- 102100023884 Probable ribonuclease ZC3H12D Human genes 0.000 description 1
- 102400000755 Processed cyclic AMP-responsive element-binding protein 3 Human genes 0.000 description 1
- 108700025701 Retinoblastoma Genes Proteins 0.000 description 1
- 108050002653 Retinoblastoma protein Proteins 0.000 description 1
- 101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 230000010632 Transcription Factor Activity Effects 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 101150073031 cdk2 gene Proteins 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- UVCJGUGAGLDPAA-UHFFFAOYSA-N ensulizole Chemical compound N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 150000002742 methionines Chemical class 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 101800000629 p34 Proteins 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000003322 phosphorimaging Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920009537 polybutylene succinate adipate Polymers 0.000 description 1
- 229920000656 polylysine Chemical group 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000037425 regulation of transcription Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000037426 transcriptional repression Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physiology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929222715A GB9222715D0 (en) | 1992-10-29 | 1992-10-29 | Transcription factor |
| GB939316206A GB9316206D0 (en) | 1993-08-05 | 1993-08-05 | Transcription factor |
| PCT/GB1993/002227 WO1994010307A1 (fr) | 1992-10-29 | 1993-10-29 | Facteur de transcription dp-1 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO951641D0 NO951641D0 (no) | 1995-04-28 |
| NO951641L NO951641L (no) | 1995-06-29 |
| NO323532B1 true NO323532B1 (no) | 2007-06-04 |
Family
ID=26301878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19951641A NO323532B1 (no) | 1992-10-29 | 1995-04-28 | Fremgangsmate for identifisering av kjemoterapeutiske midler ved bruk av transkripsjonsfaktor DP-1 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US5863757A (fr) |
| EP (2) | EP0905236A1 (fr) |
| JP (1) | JP3633616B2 (fr) |
| KR (1) | KR950704484A (fr) |
| AT (1) | ATE181360T1 (fr) |
| AU (1) | AU675678B2 (fr) |
| CA (1) | CA2148258A1 (fr) |
| DE (1) | DE69325383T2 (fr) |
| DK (1) | DK0669976T3 (fr) |
| NO (1) | NO323532B1 (fr) |
| NZ (1) | NZ257181A (fr) |
| WO (1) | WO1994010307A1 (fr) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1350514A3 (fr) * | 1993-10-29 | 2004-07-07 | The Brigham And Women's Hospital, Inc. | Utilisation thérapeutique de leurres d'élements cis in vivo |
| GB9413327D0 (en) * | 1994-07-01 | 1994-08-24 | Medical Res Council | Assay for inhibitors of dp-1 |
| WO1996015243A1 (fr) * | 1994-11-15 | 1996-05-23 | Prolifix Limited | Facteur de transcription e2f-4 |
| US6303335B1 (en) | 1994-11-15 | 2001-10-16 | Prolifix Limited | Transcription factor E2F-4 |
| GB9502873D0 (en) * | 1995-02-14 | 1995-04-05 | Medical Res Council | Transcription factor |
| US5705350A (en) * | 1995-08-29 | 1998-01-06 | Duke University | Transcription factor complexes in senescent cells |
| GB9608143D0 (en) * | 1996-04-19 | 1996-06-26 | Ver Nl Kanker Inst | Assay |
| US6159691A (en) * | 1996-05-15 | 2000-12-12 | Prolifix Limited | Assay for a putative regulator of cell cycle progression |
| GB9610195D0 (en) * | 1996-05-15 | 1996-07-24 | Medical Res Council | Assay |
| FR2750705B1 (fr) * | 1996-07-04 | 1998-10-30 | Centre Nat Rech Scient | Systeme de detection des interactions proteine-proteine |
| US6713449B1 (en) * | 1996-09-30 | 2004-03-30 | Kyowa Hakko Kogyo Co., Ltd. | E2F activity inhibitory compounds |
| US6387649B1 (en) | 1996-09-30 | 2002-05-14 | Prolifix Limited | Assay for a regulator of cell cycle progression |
| GB9626589D0 (en) * | 1996-12-20 | 1997-02-05 | Prolifix Ltd | Peptides |
| US5932425A (en) * | 1997-02-18 | 1999-08-03 | Signal Pharmaceuticals, Inc. | Compositions and methods for modulating cellular NF-κB activation |
| AU9550198A (en) | 1997-10-21 | 1999-05-10 | University Court Of The University Of Glasgow, The | Jmy, a co-activator for p300/cbp, nucleic acid encoding jmy and uses thereof |
| WO1999053075A2 (fr) * | 1998-04-09 | 1999-10-21 | E.I. Du Pont De Nemours And Company | Proteines de regulation du cycle cellulaire cdc-16, dp-1, dp-2 et e2f tirees de plantes |
| AU6976300A (en) * | 1999-09-16 | 2001-04-17 | Mcgill University | Methods for modulating cell proliferation |
| EP1214436A2 (fr) * | 1999-09-24 | 2002-06-19 | Consejo Superior De Investigaciones Cientificas | Proteines du reactif associe de dimerisation (dp) du ble et utilisations correspondantes |
| GB9923306D0 (en) | 1999-10-01 | 1999-12-08 | Isis Innovation | Diagnostic and therapeutic epitope, and transgenic plant |
| US20030225012A1 (en) * | 2002-05-31 | 2003-12-04 | Isis Pharmaceuticals Inc. | Antisense modulation of transcription factor DP-1 expression |
| GB0212885D0 (en) | 2002-06-05 | 2002-07-17 | Isis Innovation | Therapeutic epitopes and uses thereof |
| EP1755639B1 (fr) | 2004-04-28 | 2017-08-16 | BTG International Limited | Epitopes associes a une maladie coeliaque |
| US10105437B2 (en) | 2004-04-28 | 2018-10-23 | Btg International Limited | Epitopes related to coeliac disease |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993015227A1 (fr) * | 1992-01-29 | 1993-08-05 | Duke University | Procede d'evaluation de l'etat tumorigene des cellules |
-
1993
- 1993-10-29 NZ NZ257181A patent/NZ257181A/en not_active IP Right Cessation
- 1993-10-29 JP JP51083394A patent/JP3633616B2/ja not_active Expired - Fee Related
- 1993-10-29 US US08/428,131 patent/US5863757A/en not_active Expired - Fee Related
- 1993-10-29 CA CA002148258A patent/CA2148258A1/fr not_active Abandoned
- 1993-10-29 DK DK93923642T patent/DK0669976T3/da active
- 1993-10-29 EP EP98116853A patent/EP0905236A1/fr not_active Withdrawn
- 1993-10-29 AU AU53439/94A patent/AU675678B2/en not_active Ceased
- 1993-10-29 KR KR1019950701639A patent/KR950704484A/ko not_active Application Discontinuation
- 1993-10-29 DE DE69325383T patent/DE69325383T2/de not_active Expired - Fee Related
- 1993-10-29 AT AT93923642T patent/ATE181360T1/de not_active IP Right Cessation
- 1993-10-29 WO PCT/GB1993/002227 patent/WO1994010307A1/fr active IP Right Grant
- 1993-10-29 EP EP93923642A patent/EP0669976B1/fr not_active Expired - Lifetime
-
1995
- 1995-04-28 NO NO19951641A patent/NO323532B1/no not_active IP Right Cessation
-
1998
- 1998-05-14 US US09/078,596 patent/US6150116A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO1994010307A1 (fr) | 1994-05-11 |
| EP0905236A1 (fr) | 1999-03-31 |
| DE69325383D1 (de) | 1999-07-22 |
| DK0669976T3 (da) | 2000-01-10 |
| EP0669976A1 (fr) | 1995-09-06 |
| JPH08503128A (ja) | 1996-04-09 |
| NO951641D0 (no) | 1995-04-28 |
| EP0669976B1 (fr) | 1999-06-16 |
| JP3633616B2 (ja) | 2005-03-30 |
| NO951641L (no) | 1995-06-29 |
| KR950704484A (ko) | 1995-11-20 |
| US6150116A (en) | 2000-11-21 |
| AU5343994A (en) | 1994-05-24 |
| CA2148258A1 (fr) | 1994-05-11 |
| ATE181360T1 (de) | 1999-07-15 |
| NZ257181A (en) | 1997-07-27 |
| DE69325383T2 (de) | 1999-11-25 |
| AU675678B2 (en) | 1997-02-13 |
| US5863757A (en) | 1999-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO323532B1 (no) | Fremgangsmate for identifisering av kjemoterapeutiske midler ved bruk av transkripsjonsfaktor DP-1 | |
| Tevosian et al. | HBP1: a HMG box transcriptional repressor that is targeted by the retinoblastoma family. | |
| Lee et al. | Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. | |
| Bengal et al. | Functional antagonism between c-Jun and MyoD proteins: a direct physical association | |
| Girling et al. | A new component of the transcription factor DRTF1/E2F | |
| Qin et al. | The transcription factor E2F-1 is a downstream target of RB action | |
| TRAVER et al. | RGS14 is a novel Rap effector that preferentially regulates the GTPase activity of Gαo | |
| Rodriguez et al. | Functional characterization of human nucleosome assembly protein-2 (NAP1L4) suggests a role as a histone chaperone | |
| Welch et al. | RanBP3 contains an unusual nuclear localization signal that is imported preferentially by importin-α3 | |
| Chakraborty et al. | Inefficient homooligomerization contributes to the dependence of myogenin on E2A products for efficient DNA binding | |
| JP2000166555A (ja) | Ｉｇｆ―１レセプタ―と相互作用するタンパク質、それをコ―ドする遺伝子及びそれらの使用 | |
| EP0898580A1 (fr) | Procedes et moyens destines a inhiber l'activite de cdk4 | |
| JPH11313686A (ja) | サイクリン依存性キナ―ゼの阻害剤の結合パ―トナ―、並びにそれらの阻害剤検索および疾病の診断または治療のための使用 | |
| JP2006340730A (ja) | 転写因子−ｅ２ｆ−５ | |
| Sardet et al. | E2Fs and the retinoblastoma protein family | |
| CA2370098C (fr) | Proteine humaine beta-trcp | |
| Wilson et al. | Binding of HTLV-1 tax oncoprotein to the precursor of interleukin-16, a T cell PDZ domain-containing protein | |
| JP2001510684A (ja) | アッセイ、治療法及び治療手段 | |
| Shiyanov et al. | p27Kip1 induces an accumulation of the repressor complexes of E2F and inhibits expression of the E2F-regulated genes. | |
| US8889408B2 (en) | Factor taking part in transcription control | |
| US7160677B1 (en) | Transcription factor DP-1 | |
| US7141650B2 (en) | Cap-binding protein | |
| ZALC et al. | RGS14 is a novel Rap effector that preferentially regulates the GTPase activity of Gαo | |
| Eilers | MondoA and Mlx: two novel members of the basic helix-loop-helix leucine zipper family of transcription factors | |
| Lele | Transcriptional control of the gene for cyclin A1 and kinetic analysis of mutant cyclin A1/CDK complexes associated with infertility |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |